Anti-Infliximab Antibodies

Ideal for bioanalytical assays supporting preclinical research and clinical drug monitoring

Ready-made recombinant, anti-idiotypic monoclonal antibodies, highly specific for the chimeric antibody drug infliximab (Remicade®).

Type 1 anti-idiotypic antibody

Anti-Infliximab Type 1 Antibodies

The Type 1 anti-infliximab antibodies inhibit the binding of the drug infliximab to its target TNFα, and therefore detect free drug. These antibodies are ideal for use in direct ELISA, pharmacokinetic (PK) bridging assays and to develop and calibrate immune response (IR) assays to measure the anti-drug antibody (ADA) response in patient sera.

Product codes: HCA212, HCA213, HCA213P, HCA233, HCA234

Type 2 anti-idiotypic antibody

Anti-Infliximab Type 2 Antibodies

The Type 2 anti-infliximab antibodies do not inhibit the binding of infliximab to TNFα and can therefore detect total drug – free, partially bound and fully bound. These fully human antibodies can be used to measure the infliximab levels in patient sera.

Product codes: HCA214, HCA215, HCA216, HCA216P

Antibody generation using HuCAL® technology results in highly specific and sensitive antibodies, which are ideal for PK and PD assays. Antibodies are fully human, so are also perfect as controls or calibrators for ADA assays. The in vitro production of recombinant antibodies means that there is a consistent, secure supply throughout preclinical development and clinical trials, avoiding the need to develop new reagents.

More information about anti-idiotypic antibodies and their binding types and properties

Anti-biotherapeutic antibody quality control and characterization


Antibodies Specific to Infliximab

Product Code Clone Antibody Specificity Binding Type Format Affinity KD, nM Assay Development Recommendations
HCA212 AbD17837 Infliximab Type 1 Fab-V5Sx21 0.9 PK bridging ELISA capture antibody
Inhibition ELISA
HCA213 AbD17841_hIgG1 Infliximab Type 1 Human IgG1 1.8* PK bridging ELISA detection antibody
ADA assay
Inhibition ELISA
HCA213P AbD17841_hIgG1 Infliximab Type 1 Human IgG1
HRP labeled
1.8* PK bridging ELISA detection antibody
Inhibition ELISA
HCA233 AbD20436_hIgG1 Infliximab Type 1 Human IgG1 0.12* PK bridging ELISA detection antibody
ADA assay
Inhibition ELISA
HCA234 AbD20436 Infliximab Type 1 Monovalent
Fab-FH2
0.12 PK bridging ELISA capture antibody
Inhibition ELISA
HCA214 AbD19376 Infliximab &
Infliximab/TNFα complex
Type 2 Monovalent
Fab-FH2
0.7 PK bridging ELISA capture antibody
HCA215 AbD19370_hIgG1 Infliximab & Infliximab/TNFα complex Type 2 Human IgG1 1.4* PK bridging ELISA detection antibody
HCA216 AbD19376_hIgG1 Infliximab &
Infliximab/TNFα complex
Type 2 Human IgG1 0.7* PK bridging ELISA detection antibody
HCA216P AbD19376_hIgG1 Infliximab &
Infliximab/TNFα complex
Type 2 Human IgG1
HRP labeled
0.7* PK bridging ELISA detection antibody

Table 1 Antibody Specifications
1  V5=V5 tag Sx2=StrepX-StrepX-tag 
2  F=DYKDDDDK-tag H=His-6-tag
*Affinity measured in the monovalent Fab format

Related Product

Infliximab drug target Recombinant human TNF alpha (PHP051)


Pharmacokinetic Assay - Bridging Format

Pharmacokinetic (PK) Assay

Schematic image of PK Bridging ELISA. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP

PK bridging ELISA using antibodies HCA212 and HCA213

Figure 1: PK bridging ELISA using antibodies HCA212 and HCA213

Human anti-infliximab antibodies, product codes HCA212 and HCA213

Figure 1: Anti-infliximab antibody, clone AbD17837 (HCA212), was coated on a microtiter plate at 1.0 µg/ml and left overnight. Infliximab was then spiked in human serum and added in increasing concentrations as indicated. Detection was performed by adding HRP conjugated anti-infliximab antibody clone AbD17841_hIgG1 (HCA213P). The data are shown as the mean of three measurements.


Anti-Drug Antibody Assay - Bridging ELISA

Anti-Drug Antibody Assay

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue)

Figure 2: ADA assay, bridging ELISA format using antibody HCA213

Human anti-infliximab antibody, product code HCA213

Figure 2: Infliximab was coated at 1.0 µg/ml on a microtiter plate and left over night. Washing and blocking was performed with 5% BSA in PBST. Anti-infliximab antibody, clone AbD17841_hIgG1 (HCA213), titrated into 10% human serum was then added. Detection was performed by adding HRP conjugated infliximab at 4.0 µg/ml in  HISPEC buffer (BUF049A) plus QuantaBlu™ fluorogenic peroxidase substrate. The data are shown as the mean of three measurements.


Inhibition ELISA

Human anti-infliximab antibodies, product codes HCA213 and HCA215

Figures 3 and 4: Anti-infliximab antibody was coated at 5.0 µg/ml on a microtiter plate and left over night. Washing and blocking was performed with 5% BSA in PBST. HCA213  and HCA215 were used in a monovalent Fab format. The following was then added at the given concentrations:

Infliximab alone (no TNFα)
Infliximab and a 5.0-fold molar excess of TNFα

Infliximab still capable of binding to the immobilized anti-infliximab antibody was detected by adding HRP conjugated anti-human Fc-specific IgG antibody (MCA647P), plus QuantaBlu fluorogenic peroxidase substrate.

Figure 3: Anti-infliximab antibody HCA215 binds both infliximab and the infliximab/TNFα complex

Figure 4: Anti-infliximab antibody HCA213 is specific for unbound infliximab and does not bind to the infliximab/TNFα complex


Inhibition of infliximab binding to TNFα

Figure 5: Inhibition of infliximab binding to TNFα by antibody HCA213

Human anti-infliximab antibody, product code HCA213

Figure 5: TNFα was coated on a microtiter plate at 1.0 µg/ml.  Following coating, a pre-incubated mixture of the anti-infliximab antibody (HCA213), titrated into a constant amount of infliximab (IFX, 0.3 µg/ml) was added. Free infliximab still capable of binding to the plate was detected using HRP conjugated anti-human Fc-specific IgG (MCA647P). The data are shown as the mean of three measurements.


Demonstration of Antibody Specificity

Human anti-infliximab antibody, product code HCA213

Figure 6: Antigens were coated at 5 µg/ml on a microtiter plate over night.  After washing and blocking with 5% milk powder in PBST, HRP conjugated anti-infliximab antibody (HCA213P) was added.  Detection was performed using the QuantaBlu fluorogenic peroxidase substrate.

Non-inhibitory Type 2 antibodies HCA214, HCA215, HCA216 and HCA216P recognize an epitope on infliximab that is shared by other closely related chimeric antibodies, such as cetuximab.  These anti-infliximab antibodies have been shown to bind to the chimeric antibody cetuximab, but they do not bind to the chimeric antibody rituximab.


Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

REMICADE® is a registered trademark of Janssen Biotech, Inc. USA. HuCAL® is a registered trademark of MorphoSys AG. QuantaBlu™ is a trademark of Thermo Fisher Scientific.